ET-1 blocking treatments caused dose-dependent inhibition of vascular smooth muscle cell proliferation, achieving a 90% inhibitory effect at maximum doses.
Autocrine effects of ET-1 play a predominant role in the proliferation of vascular smooth muscle cells from SHR and WKY rats, and mediate thrombin-induced but not angiotensin II-induced growth.
According to previous studies, endothelin-1 (ET-1) is the most potent growth factor in the regulation of vascular smooth muscle cell (VSMC) proliferation in spontaneously hypertensive rats (SHR). To evaluate if the dominant effect of ET-1-induced VSMC proliferation is achieved by autocrine regulation, aortic smooth muscle cells from four-week-old SHR and WKY (Wistar-Kyoto) rats were cultured in 24-well dishes, and the effects of ET-1 on VSMC proliferation were determined by (a) 3H-thymidine incorporation assays with different ET-1 blocking treatments, including a specific anti-ET-1 antibody; BQ-123, an ETA receptor blocker; and BQ-788, an ETB receptor blocker; and (b) examining the ET-1 blockade on the effects of treatment with other growth factors, including thrombin and angiotension II (AT-II). These results demonstrated that the anti-ET-1 antibody, BQ-123, BQ-788, and BQ-123 plus BQ-788 all caused dose-dependent inhibition of proliferation. A 90% inhibitory effect was observed at the maximum doses used except for BQ-123. The ET-1 receptor blockers inhibited thrombin-induced VSMC growth; however, they did not efficiently inhibit AT-II-induced VSMC growth. These results indicate that the autocrine effects of ET-1 play a predominant role in the proliferation of VSMCs from SHR and WKY rats. They also suggest that thrombin-induced VSMC growth is mediated by the autocrine effects of ET-1, and angiotensin II-induced VSMC growth is mediated by other signal pathways.
Lu et al. (Sun,) conducted a other in Hypertension. ET-1 blocking treatments (anti-ET-1 antibody, BQ-123, BQ-788) was evaluated on Vascular smooth muscle cell (VSMC) proliferation determined by 3H-thymidine incorporation. ET-1 blocking treatments caused dose-dependent inhibition of vascular smooth muscle cell proliferation, achieving a 90% inhibitory effect at maximum doses.